Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis - PubMed

7 hours ago

Ecnoglutide, a novel long-acting GLP-1 receptor agonist, shows promise for treating Type 2 Diabetes Mellitus (T2DM), which affects over 500 million people globally.
A meta-analysis of four randomized controlled trials (total 1643 participants) found ecnoglutide significantly reduces HbA1c, body weight, and fasting plasma glucose, with improvements in insulin sensitivity, lipid profile, and liver enzymes.
Adverse events, primarily gastrointestinal and mild-to-moderate, were more common with ecnoglutide, but serious adverse events did not differ significantly from comparators.
The study concludes that ecnoglutide offers robust efficacy for glycemic control and weight reduction with an acceptable safety profile, supporting its potential as a next-generation GLP-1 agonist.

Hasty Briefsbeta